ABSTRACT
Though the effect of the coronavirus has known to be a catastrophic pandemic since a 100 years ago, severe acute respiratory syndrome-2 coronavirus (SARS2-CoV) was first claimed to be emerged in December 2019 at the city of Wuhan, China. Abruptly, the virus dominated more than 218 countries with 157,566,607 confirmed cases and the death figure has reached nearly 3,284,551 till time. Recently the pandemic is getting worse day-by-day, people are suffering from hypoxia and severe respiratory problems despite the continuous services provided by the healthcare sector. Prior concern behind this emergency is that, till date, researchers and scientists failed to invent any productive pharmaceutical treatment to weed out the infection completely. Although vaccination is publicly available, it is applicable only for precautionary purposes and not evident of preventive measures. This review focuses on the therapeutic status to control the severity of SAS2-CoV agent. The approach aims at implicating a low toxic metabolite anti-malarial drug, hydroxychloroquine combined with an antibiotic called azithromycin for the treatment of acute respiratory disturbance and hypoxia. This article briefly demonstrates the phramaco-potential of both these medications, their effects on patients based on a clinical observation and ongoing status of dosage to validate its implication.